Mustang Bio Inc (NASDAQ:MBIO) Director Lindsay A. Md Rosenwald bought 50,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The shares were bought at an average cost of $4.41 per share, for a total transaction of $220,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of MBIO stock opened at $4.44 on Tuesday. Mustang Bio Inc has a 1 year low of $3.70 and a 1 year high of $12.89. The firm has a market cap of $126.77 million, a P/E ratio of -5.92 and a beta of 1.66.
Mustang Bio (NASDAQ:MBIO) last posted its quarterly earnings results on Monday, August 13th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.06. On average, analysts expect that Mustang Bio Inc will post -0.84 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of MBIO. Northern Trust Corp boosted its stake in Mustang Bio by 76.7% during the first quarter. Northern Trust Corp now owns 28,364 shares of the company’s stock worth $310,000 after buying an additional 12,316 shares in the last quarter. BlackRock Inc. boosted its stake in Mustang Bio by 904.5% during the first quarter. BlackRock Inc. now owns 21,646 shares of the company’s stock worth $237,000 after buying an additional 19,491 shares in the last quarter. A.R.T. Advisors LLC acquired a new stake in Mustang Bio during the first quarter worth $186,000. Millennium Management LLC boosted its stake in Mustang Bio by 271.7% during the first quarter. Millennium Management LLC now owns 101,029 shares of the company’s stock worth $1,105,000 after buying an additional 73,850 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Mustang Bio by 252.4% during the second quarter. Bank of New York Mellon Corp now owns 43,557 shares of the company’s stock worth $300,000 after buying an additional 31,197 shares in the last quarter. Hedge funds and other institutional investors own 9.52% of the company’s stock.
A number of brokerages recently issued reports on MBIO. ValuEngine lowered shares of Mustang Bio from a “hold” rating to a “sell” rating in a research report on Wednesday, October 17th. Zacks Investment Research raised shares of Mustang Bio from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Saturday, August 18th. Finally, Oppenheimer set a $18.00 target price on shares of Mustang Bio and gave the stock a “buy” rating in a research report on Tuesday, October 30th.
WARNING: “Mustang Bio Inc (MBIO) Director Lindsay A. Md Rosenwald Purchases 50,000 Shares” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/11/06/mustang-bio-inc-mbio-director-lindsay-a-md-rosenwald-purchases-50000-shares.html.
About Mustang Bio
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma.
Recommended Story: Closed-End Mutual Funds
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.